A Pilot Study of Rapid Autopsy and Procurement of Tissue in Non-Small Cell Lung Cancer Patients to Investigate Tumor Heterogeneity
- Despite being the leading cause of cancer-related death worldwide, there is only
limited knowledge of tumor heterogeneity in NSCLC.
- Tumor heterogeneity can be evaluated in a comprehensive manner by deep sequencing and
global analysis of genomic and proteomic alterations of simultaneous core biopsies from
several areas of the primary tumor and metastases and correlation with clinical
outcome. However such studies are not feasible in a clinical setting.
- Tissue procurement by rapid autopsies provides an effective way for such an
- Clonal evolution and selection of tumor cells can be assessed by examining genomic and
proteomic alterations of tumor samples obtained from multiple sites of primary and
- Procure primary NSCLC and metastatic tissue shortly after death in order to investigate
tumor heterogeneity- both intratumor and between paired primary and metastatic site, using
integrated genomic and proteomic analysis.
- Adult patients with metastatic NSCLC with life expectancy less than or equal to 3 months
- Ten patients will be autopsied in this pilot study.
- Patients will be admitted for inpatient hospice when an investigator estimates a
survival of less than 2 weeks.
- Upon expiration, rapid autopsy will be performed and tissue obtained from primary tumor
site if still identifiable, and multiple metastatic sites to assess tumor heterogeneity
using deep sequencing and global genomic and proteomic analyses.
- Archival tissue from patients, if available, will be used to evaluate these changes
from several stages of tumor progression.
Time Perspective: Prospective
Tumor tissue from multiple anatomical sites obtained
within 3 hours after death
Udayan Guha, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|